{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T13:44:52Z","timestamp":1776606292540,"version":"3.51.2"},"reference-count":35,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2005,11,15]],"date-time":"2005-11-15T00:00:00Z","timestamp":1132012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Associate Editor<\/jats:p>\n                    <jats:p>Michael G. Wylie<\/jats:p>\n                    <jats:p>Editorial Board<\/jats:p>\n                    <jats:p>Ian Eardley, UK<\/jats:p>\n                    <jats:p>Jean Fourcroy, USA<\/jats:p>\n                    <jats:p>Sidney Glina, Brazil<\/jats:p>\n                    <jats:p>Julia Heiman, USA<\/jats:p>\n                    <jats:p>Chris McMahon, Australia<\/jats:p>\n                    <jats:p>Bob Millar, UK<\/jats:p>\n                    <jats:p>Alvaro Morales, Canada<\/jats:p>\n                    <jats:p>Michael Perelman, USA<\/jats:p>\n                    <jats:p>Marcel Waldinger, Netherlands<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>To compare treatment preference, efficacy, and tolerability of sildenafil citrate (sildenafil) and tadalafil for treating erectile dysfunction (ED) in men na\u00efve to phosphodiesterase 5 (PDE5) inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>This was an open\u2010label, crossover study of sildenafil and tadalafil (taken as needed). After a 4\u2010week baseline assessment, 367 men with ED (mean age 54\u2003years) were randomized to receive sildenafil for 12\u2003weeks followed by tadalafil for 12\u2003weeks or vice versa (8\u2010week dose optimization and 4\u2010week assessment phases). During dose optimization, patients started taking 25\u2010 or 50\u2010mg sildenafil or 10\u2010mg tadalafil and could titrate to find their optimum dose (25\u2010, 50\u2010 or 100\u2010mg sildenafil; 10\u2010 or 20\u2010mg tadalafil). After completing both 12\u2010week periods, patients chose which treatment to continue during an 8\u2010week extension. Efficacy was measured with the International Index of Erectile Function (IIEF) and Sexual Encounter Profile (SEP) diary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Of the 291 men who completed both treatments, 85 (29%) chose sildenafil and 206 (71%) chose tadalafil (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001) for the 8\u2010week extension. The IIEF erectile function domain scores were 14.2 at baseline, 23.9 at endpoint on sildenafil, and 24.3 at endpoint on tadalafil (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.08, sildenafil vs tadalafil). The mean per patient percentage success scores for SEP2 (penetration) were: baseline (46%), sildenafil (post\u2010baseline 82%) and tadalafil (post\u2010baseline 85%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.06, sildenafil vs tadalafil), and for SEP3 (successful intercourse) were: baseline (19%), sildenafil (post\u2010baseline 72%), and tadalafil (post\u2010baseline 77%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.003, sildenafil vs tadalafil). The only treatment\u2010emergent adverse events that were reported by &gt;5% of men were headache and flushing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In men with ED who were na\u00efve to PDE5 inhibitor therapy, sildenafil and tadalafil were both effective and well tolerated. After treatment with sildenafil and tadalafil, 29% of men chose sildenafil and 71% chose tadalafil for ED therapy during an 8\u2010week extension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2005.05892.x","type":"journal-article","created":{"date-parts":[[2005,11,15]],"date-time":"2005-11-15T05:16:57Z","timestamp":1132031817000},"page":"1323-1332","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["An open\u2010label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men na\u00efve to phosphodiesterase 5 inhibitor therapy"],"prefix":"10.1111","volume":"96","author":[{"given":"Ian","family":"Eardley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Mirone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Kell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret R.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Beardsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,11,15]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)34871-1"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00215-X"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900269"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201093260203"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805143382001"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64442-4"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1939-4640.2002.tb02332.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006153422407"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.00128.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04819.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1549-6"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68179-7"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3101617"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00075-4"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000136448.71773.2b"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.5.421"},{"key":"e_1_2_8_18_2","unstructured":"European Medicines Agency.Cialis (tadalafil) Summary of Product Characteristics.http:\/\/www.emea.eu.int\/humandocs\/Humans\/EPAR\/cialis\/cialis.htm. AccessedAugust 2005"},{"key":"e_1_2_8_19_2","unstructured":"European Medicines Agency.Viagra (sildenafil) Summary of Product Characteristics.http:\/\/www.emea.eu.int\/humandocs\/Humans\/EPAR\/Viagra\/Viagra.htm. AccessedAugust 2005"},{"key":"e_1_2_8_20_2","unstructured":"Levitra (vardenafil HCI) label.http:\/\/www.univgraph.com\/bayer\/inserts\/levitra.pdf. AccessedAugust 2005"},{"key":"e_1_2_8_21_2","unstructured":"Viagra (sildenafil citrate) label.http:\/\/pfizer.com\/pfizer\/download\/uspi_viagra.pdf. AccessedAugust 2005"},{"key":"e_1_2_8_22_2","unstructured":"Cialis (tadalafil) label.http:\/\/www.fda.gov\/cder\/foi\/label\/2003\/021368lbl.pdf. AccessedAugust 2005"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2004.04023.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901227"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)00945-1"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80328-4"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.11.030"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80329-6"},{"key":"e_1_2_8_29_2","unstructured":"DeanJ HackettG GentileVet al.Psychological and interpersonal outcomes in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction in an open label crossover study. Abstract presented at the World Congress of Sexology Montreal Quebec Canada July 2005:403\u2013404 abstract 3133. Accessed August 2005http:\/\/www.montrealsexo.com\/en\/sexoabstracts.pdf"},{"key":"e_1_2_8_30_2","unstructured":"DeanJ HackettG GentileVet al.Drug attributes influencing the choice of sildenafil citrate and tadalafil for the treatment of erectile dysfunction in an open label crossover study. Abstract presented at the World Congress of Sexology Montreal Quebec CanadaJuly 2005:409 abstract 3144. Accessed August 2005http:\/\/www.montrealsexo.com\/en\/sexoabstracts.pdf"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00099-0"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00238-0"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00643-8"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04816.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.11.010"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042307-200411000-00013"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2005.05892.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2005.05892.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:45:49Z","timestamp":1761731149000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2005.05892.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,15]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1111\/j.1464-410X.2005.05892.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2005.05892.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,15]]},"assertion":[{"value":"2005-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}